

HAP Medicare Part B Drugs Requiring Step Therapy

Last update 4/16/24

| NON-Preferred Part B Drugs Step Therapy Required | Generic/Biosimilar name | Preferred Part B Drugs alternatives | Generic/Biosimilar Name |
|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------------|
| Rituxan Riabni Rituxan Hycela | Rituximab Rituximab-arrx Rituximab hyaluronidase | Truxima Ruxience | Rituximab-abbs Rituximab-pvvr |
| Herceptin Ogivri Ontruzant Herzuma Herceptin Hylecta | trastuzumab trastuzumab-dkst trastuzumab-dttb trastuzumab-pkrb trastuzumab/ hyaluronidase-oysk | Kanjinti Trazimera | Trastuzumab-anns Trastuzumab-qyyp |
| Phesgo | Pertuzumab/trastuzumab-hyaluronidase-zxxf | Kanjinti Trazimera Perjeta | Trastuzumab-anns Trastuzumab-qyyp Pertuzumab |
| Remicade Avsola Ixifix | Infliximab Infliximab-axxq Infliximab-qbt | Renflexis Inflecta | Infliximab-abda Infliximab-dyyb |
| Fulphila Ziextenzo Rolvedon Stimufed Fylnetra | Pegfilgrastim-jmbd Pegfilgrastim-bmez Eflapegrastim-xnst Pegfilgrastim-fpgk Pegfilgrastim-pbbk | Neulasta Udeneca Nyvepria | Pegfilgrastim Pegfilgrastim-cbqv Pegfilgrastim-apgf |
| Avastin* *auth not required for eye related conditions Alymsys Vegzelma | Bevacizumab Bevacizumab-maly Bevacizumab-adcd | Mvasi Zirabev | Bevacizumab-awwb Bevacizumab-bvzr |
| Eylea Lucentis Beovu Byooviz Cimerli | Aflibercept Ranibizumab Brolucizumab Ranibizumab-nuna Ranibizumab-eqrn | Avastin | bevacizumab |
| Eylea HD Vabsymo | Aflibercept Faricimab-svoa | Eylea | Aflibercept |
| Susvimo (implant) | Ranibizumab | Lucentis | ranibizumab |

HAP Medicare Part B Drugs Requiring Step Therapy

Last update 4/16/24

| | | | |
|--------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-------------------------------------------------------------|
| Leqvio | Inclisiran | Repatha | evolocumab |
| Vyvgart Rystiggo | Efgartigimod-fcab Rozanolixizumab-noli | One of the following: azathioprine, mycophenolate, cyclosporine, or tacrolimus | Azathioprine, mycophenolate, cyclosporine, or tacrolimus |
| Vyvgart hyrtulo | Efgartigimod alfa and hyaluronidase-qvfc | Vyvgart Rystiggo | Efgartigimod-fcab Rozanolixizumab-noli |
| Soliris | Eculizumab | | |
| Ultomiris | Ravulizumab | | |
| Izervay | Avacincaptad pegol | Syfovre | Pegcetacoplan |
| Entyvio Skyrizi Stelara Omvoh Simponi Aria Cosentyx | Vedolizumab Risankizumab Ustekinumab Mirikizumab-mrkz Golimumab Secukinumab | Hadlima | Adalimumab-bwwd |
| Spevigo | Spesolimab-sbzo | One of the following: cyclosporine, methotrexate, or acitretin. | Cyclosporin, methotrexate, or acitretin. |

Step Therapy requirements apply to certain Part B drugs. Step Therapy is a utilization tool that requires you to first try other drugs to treat your medical condition before we will cover the drug your physician may have initially prescribed. Currently, the plan has Step Therapy in place for the drugs listed above. The preferred drugs must be tried before the non-preferred product can be authorized or your doctor can tell us the reason the preferred drug is not right for you. The list will be updated as additional drugs are added to the Part B drug Step Therapy program.

Approval of a prior authorization request for a course of treatment is valid for as long as it is medically necessary to avoid disruptions in care. In accordance with applicable coverage criteria, medical history, and the treating provider's recommendation.

A 90-day transition period for any active course(s) of treatment for members new to the plan after starting a course of treatment, even if the service is furnished by an out-of-network provider. This includes enrollees new to a plan and enrollees new to Medicare. HAP will not disrupt or require reauthorization for an active course of treatment for new members for a period of at least 90 days.

HAP Medicare Part B Drugs Requiring Step Therapy

Last update 4/16/24

Your doctor can submit a prior authorization for a drug on this list using the HAP Provider Portal on www.hap.org.